Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup (Bordeaux)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02593747
Recruitment Status : Completed
First Posted : November 1, 2015
Last Update Posted : February 13, 2017
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
To assess the bioequivalence of Loratadine Oral Solution/Syrup 1mg/mL (GPLA Formula) versus Claritin Peach Syrup 1mg/mL (ANNA Formula)

Condition or disease Intervention/treatment Phase
Histamine H1 Antagonists, Non-Sedating Drug: Loratadine oral solution Drug: Loratadine (Claritin peach syrup) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-dose, Single-center, Randomized, Open-label, Two-way Crossover Study in Healthy Adults to Assess the Bioequivalence of Loratadine Oral Solution/Syrup 1mg/mL (GPLA Formula) Versus Claritin Peach Syrup 1mg/mL (ANNA Formula)
Study Start Date : December 2015
Actual Primary Completion Date : January 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Loratadine

Arm Intervention/treatment
Experimental: Loratadine oral solution/syrup then Claritin peach syrup
Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
Drug: Loratadine oral solution
Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.

Drug: Loratadine (Claritin peach syrup)
Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.

Experimental: Claritin peach syrup then Loratadine oral solution/syrup
Subjects received a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
Drug: Loratadine oral solution
Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.

Drug: Loratadine (Claritin peach syrup)
Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.




Primary Outcome Measures :
  1. Primary: Area Under the Concentration Versus Time Curve From Zero to the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) of Loratadine in Plasma (AUC[0-tlast]) After Single Oral Dose of Loratadine [ Time Frame: 0 hour (h) (pre-dose) to 72 h post-dose ]
    Area under the concentration versus time curve from zero to the last data point greater than (>) LLOQ (AUC[0-tlast]) after single dose.

  2. Maximum Observed Concentration (Cmax) of Loratadine in Plasma After Single Oral Dose of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Maximum observed loratadine concentration in plasma, directly taken from analytical data.


Secondary Outcome Measures :
  1. Time to Reach Maximum Concentration (tmax) in Plasma After Single Dose of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Time to reach maximum loratadine concentration in plasma after its single oral dose, directly taken from analytical data.

  2. Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of Loratadine in Plasma After Single Dose [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Area under the concentration versus time curve from zero to infinity after single dose.

  3. Half-Life (t1/2) Associated With the Terminal Slope of Loratadine After Single Dose [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Half-life associated with the terminal slope.

  4. Total Body Clearance (CL/F) of Loratadine Calculated After its Single Oral Administration [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Total body clearance of loratadine calculated after extravascular application.

  5. Percentage of Area Under the Concentration Versus Time Curve (AUC) From the Last Calculated Data Point Greater Than Lower Limit of Quantification [LLOQ]) to Infinity (%AUC[tlast-∞]) After Single Oral Administration of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Percentage of AUC from the last calculated data point > LLOQ to infinity was measured.

  6. Apparent Terminal Rate Constant (λz) of Loratadine After Single Dose [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Apparent terminal rate constant, calculated from the slope of a log-linear regression of the unweighted data considering the last concentration-time points > LLOQ.

  7. Area Under the Concentration Versus Time Curve From Zero to 72 Hours (AUC[0-72]) of Lloratadine in Plasma After Single Oral Dose [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Area under the concentration versus time curve from zero to 72 h after single dose.

  8. Maximum Observed Concentration (Cmax) of Desloratadine in Plasma After Single Oral Dose of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Maximum observed desloratadine concentration in plasma, directly taken from analytical data.

  9. Time to Reach Maximum Concentration (tmax) of Desloratadine in Plasma After Single Dose of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Time to reach maximum drug concentration in the measured matrix, directly observed from the analytical data.

  10. Area Under the Concentration Versus Time Curve From Zero to the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) of Desoratadine in Plasma (AUC[0-tlast]) After Single Oral Dose of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Area under the concentration versus time curve from zero to the last data point > LLOQ (AUC[0-tlast]) after single dose.

  11. Area Under the Concentration Versus Time Curve From Zero to 72 Hours (AUC[0-72]) of Desloratadine in Plasma After Single Oral Dose of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Area under the concentration versus time curve from zero to 72 h after single dose. AUC and residual area were not evaluated because the concentration at 72 h was quantifiable in the majority of profiles.

  12. Time of Last Concentration Above the Lower Limit Of Quantitation (LLOQ) of Desloratadine, Directly Taken From Analytical Data (tlast) [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Time of last concentration above LLOQ, directly taken from analytical data.

  13. Half-Life (t1/2) Associated With the Terminal Slope of Desoratadine After Single Dose of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Half-life associated with the terminal slope.

  14. Percentage of Area Under the Concentration Versus Time Curve (AUC) from the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) to Infinity (%AUC[tlast-∞]) of Desoratadine After Single Oral Administration of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Percentage of area under the concentration versus time curve from zero to the last data point > LLOQ in plasma (AUC[(0-tlast]) was measured.

  15. Apparent Terminal Rate Constant (λz) of Desoratadine After Single Dose of Loratadine [ Time Frame: 0 h (pre-dose) to 72 h post-dose ]
    Apparent terminal rate constant, calculated from the slope of a log-linear regression of the unweighted data considering the last concentration-time points > LLOQ.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult (men or women), age 18 to 55 years inclusive;
  • Body mass index 18.5 to 30.0 kg/m*2 inclusive;
  • Able to read and understand the written informed consent for study-related information and instruction;
  • Able to comply with protocol requirements, including overnight stays, blood sample collections as defined in the protocol;
  • Agree not to donate whole blood or components of blood (e.g. plasma, thrombocytes) starting from signing the informed consent form through 30 days after the last study procedure, except for the blood samples collected for this study;
  • Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, injectable contraceptive (e.g. Depo-Provera), or a double barrier and have a negative pregnancy test at Screening and prior to study drug administration on Day 0 of Dosing Periods 1 and 2. Female subjects of non-childbearing potential must be amenorrheic for at least two years or had a hysterectomy and/or bilateral oophorectomy;

Exclusion Criteria:

  • Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal;
  • Known hypersensitivity to any medication (active substances or excipients of the preparations) to be used in the study;
  • Known galactose intolerance, lactase deficiency or glucose-galactose malabsorption
  • Known severe allergies (e.g. allergies to more than 3 allergens, allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with corticosteroids);
  • Use of, within 1 month before the first study drug administration, systemic or topical medicines or substances which might affect the study objectives, e.g

    • any drug known to induce cytochrome P3A4/5 or P Glycoprotein (e.g. rifampin, carbamazepine, St. John's wort);
    • any drug known to inhibit cytochrome P3A4/5 or P Glycoprotein (e.g. erythromycin, clarithromycin, chloramphenicol, ketoconazole);
    • any drug known to induce cytochrome P2D6 (e.g. rifampin, dexamethasone);
    • any drug known to inhibit cytochrome P2D6 (e.g. cimetidine, desipramine, fluoxetine, metoclopramide);
  • Positive urine pregnancy, urine drug test or Hepatitis B, hepatitis C or HIV tests;
  • Clinically relevant findings in the physical examination, e.g., signs of bleeding diathesis, signs of heart failure, evidence of peripheral circulatory disturbances, and skin abnormalities;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02593747


Locations
Layout table for location information
Germany
Neu-Ulm, Bayern, Germany, 89231
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02593747    
Other Study ID Numbers: 18199
2015-002720-12 ( EudraCT Number )
First Posted: November 1, 2015    Key Record Dates
Last Update Posted: February 13, 2017
Last Verified: February 2017
Keywords provided by Bayer:
Allergy
Additional relevant MeSH terms:
Layout table for MeSH terms
Loratadine
Antipruritics
Dermatologic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs